Browsing Centre for Experimental Medicine and Rheumatology (EMR) by Author "Sainaghi, PP"
Now showing items 1-11 of 11
-
The Enigma of Vitamin D Role in Inflammation
Bellan, M; Nerviani, A; Sainaghi, PP (2018-12-27) -
Increased plasma levels of Gas6 and its soluble tyrosine kinase receptors Mer and Axl are associated with immunological activity and severity of lupus nephritis.
Bellan, M; Quaglia, M; Nerviani, A; Mauro, D; Lewis, M; Goegan, F; Gibbin, A; Pagani, S; Salmi, L; Molinari, L (2020-06-04)OBJECTIVES: Growth arrest-specific 6 (Gas6) and its receptors have been shown to play a crucial role in the homeostasis of the innate immune system by regulating apoptosis and inflammation. We aimed to verify whether an ... -
Is cholecalciferol a potential disease-modifying anti-rheumatic drug for the management of rheumatoid arthritis?
Bellan, M; Andreoli, L; Nerviani, A; Piantoni, S; Avanzi, GC; Soddu, D; Hayden, E; Pirisi, M; Sainaghi, PP (2020) -
New Insights into the Role of Tyro3, Axl, and Mer Receptors in Rheumatoid Arthritis
Pagani, S; Bellan, M; Mauro, D; Castello, LM; Avanzi, GC; Lewis, MJ; Sainaghi, PP; Pitzalis, C; Nerviani, A (2020-01-21) -
O07 Randomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy
Humby, FC; Lewis, M; Durez, P; Buch, MH; Bombardieri, M; Rizvi, H; Rivellese, F; Fossati, L; Hands, R; Giorli, G (2020-04-01) -
A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response - Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy
Humby, F; Buch, MH; Durez, P; Lewis, M; Bombardieri, M; Rizvi, H; Kelly, S; Fosatti, L; Hands, R; Giorli, G (2019-10) -
RANDOMISED, OPEN LABELLED CLINICAL TRIAL TO INVESTIGATE SYNOVIAL MECHANISMS DETERMINING RESPONSE: RESISTANCE TO RITUXIMAB VERSUS TOCILIZUMAB IN RA PATIENTS FAILING TNF INHIBITOR THERAPY
Humby, FC; Lewis, M; Durez, P; Buch, MH; Bombardieri, M; Rizvi, H; Rivellese, F; Fossati, L; Hands, R; Giorli, G (2020-04) -
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Humby, F; Durez, P; Buch, MH; Lewis, MJ; Rizvi, H; Rivellese, F; Nerviani, A; Giorli, G; Mahto, A; Montecucco, C (2021-01-23)BACKGROUND: Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is mechanistically still unexplained. Because more ... -
Role of Gas6 and TAM Receptors in the Identification of Cardiopulmonary Involvement in Systemic Sclerosis and Scleroderma Spectrum Disorders
Bellan, M; Dimagli, A; Piccinino, C; Giubertoni, A; Ianniello, A; Grimoldi, F; Sguazzotti, M; Nerviani, A; Barini, M; Carriero, A (2020-05-12) -
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials
Rivellese, F; Nerviani, A; Giorli, G; Warren, L; Jaworska, E; Bombardieri, M; Lewis, MJ; Humby, F; Pratt, AG; Filer, A (2023-11-01)Background: Despite highly effective targeted therapies for rheumatoid arthritis, about 40% of patients respond poorly, and predictive biomarkers for treatment choices are lacking. We did a biopsy-driven trial to compare ... -
Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review
Bellan, M; Patrucco, F; Barone-Adesi, F; Gavelli, F; Castello, LM; Nerviani, A; Andreoli, L; Cavagna, L; Pirisi, M; Sainaghi, PP (Elsevier, 2019-12-12)